Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (2185)	11/30/2000 10:27:16 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

<<Some nice stock picks can be found if mgt has the ability to redo a phase III with strong FDA guidance.>> Mgt should better designed first two trials and protocols three years ago. No credit where isn’t deserved, my motto is. This trial is effort of new mgt. Regards the partner, my filling is that ABT (for instance) will go with 50:50. Miljenko

To: rkrw who wrote (2185)	11/30/2000 11:23:49 PM
From: Biomaven	Respond to of 52153

CORR is selling for probably 5 times 2001 integrillin sales. They have a true 50-50 with SGP. (Maybe that just means CORR is a good buy CORR is selling at about 20 times trailing 1 year revenue, and at about 10 times annual integrilin sales based on last quarter's higher sales of $50m. So actually CORR does look cheap compared with AMGN, especially as integrilin sales are finally accelerating rapidly. I didn't mean to imply that Natrecor could do $300m sales quickly - I think ramp will take a number of years. Certainly if you take CORR as your model, SCIOS doesn't look quite as cheap as I said. Still, I think there is room for some appreciation over the next six months or so. Given that this is a "redo" for the FDA, and they collaborated closely in designing the trial, hopefully they can be quicker than normal here. Peter